Northwest Financial Advisors Sells 377 Shares of Novo Nordisk A/S (NYSE:NVO)

Northwest Financial Advisors lowered its stake in Novo Nordisk A/S (NYSE:NVO) by 13.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,510 shares of the company’s stock after selling 377 shares during the period. Northwest Financial Advisors’ holdings in Novo Nordisk A/S were worth $216,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of NVO. Xponance Inc. increased its holdings in Novo Nordisk A/S by 27.6% in the 2nd quarter. Xponance Inc. now owns 2,665 shares of the company’s stock worth $380,000 after buying an additional 576 shares during the period. AQR Capital Management LLC lifted its position in shares of Novo Nordisk A/S by 110.5% during the second quarter. AQR Capital Management LLC now owns 17,164 shares of the company’s stock worth $2,450,000 after purchasing an additional 9,012 shares in the last quarter. The Manufacturers Life Insurance Company increased its position in shares of Novo Nordisk A/S by 2.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 131,876 shares of the company’s stock valued at $18,824,000 after purchasing an additional 2,817 shares during the last quarter. Scientech Research LLC purchased a new position in shares of Novo Nordisk A/S in the 2nd quarter valued at $467,000. Finally, Creative Planning boosted its stake in Novo Nordisk A/S by 8.8% during the 2nd quarter. Creative Planning now owns 281,596 shares of the company’s stock worth $40,195,000 after purchasing an additional 22,848 shares during the period. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Down 0.6 %

NYSE NVO opened at $87.45 on Tuesday. The company has a 50 day moving average of $95.35 and a 200-day moving average of $114.80. The company has a market cap of $392.43 billion, a price-to-earnings ratio of 28.30, a PEG ratio of 0.90 and a beta of 0.45. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. Novo Nordisk A/S has a 1-year low of $78.17 and a 1-year high of $148.15.

Analyst Upgrades and Downgrades

NVO has been the subject of several research analyst reports. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. BMO Capital Markets cut their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Finally, UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.